…
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
China Shineway Pharmaceutical Group Ltd develops, manufactures and sells pharmaceutical and health-related products in China. Long-term growth drivers may include rising healthcare spending, an aging population and expansion of higher-margin products or distribution that could support revenue and margin improvement. Investors may use the company for exposure to domestic pharmaceutical demand and potential portfolio progression.
Key risks include OTC Pink ADR trading and limited public reporting, which create liquidity and transparency concerns, plus exposure to Chinese regulatory changes, pricing pressure and strong domestic competition.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1234.68M | 1145.72M | 1240.25M | 917.02M | 720.10M |
| Net income | 924.07M | 840.05M | 969.51M | 722.77M | 556.67M |
| Selling general administrative | - | 291.32M | 326.50M | 2098.46M | 1756.24M |
| Selling and marketing expenses | - | 1597.31M | 1981.62M | - | - |
| Gross profit | 2204.46M | 2831.75M | 3394.12M | 2938.31M | 2410.34M |
| Reconciled depreciation | - | 68.73M | 177.10M | 185.86M | 182.39M |
| Ebit | 663.48M | 1151.85M | 1242.99M | 713.58M | 534.37M |
| Ebitda | 732.44M | 1220.59M | 1420.09M | 1103.52M | 903.74M |
| Depreciation and amortization | 68.95M | 68.73M | 177.10M | - | - |
| Operating income | 663.48M | 842.60M | 975.53M | 722.40M | 541.39M |
| Other operating expenses | 2386.51M | 2935.44M | 3379.06M | - | - |
| Interest expense | 5.53M | 6.13M | 2.74M | 0.63M | 1.25M |
| Tax provision | - | 305.67M | 270.74M | 194.25M | 163.43M |
| Interest income | - | 176.72M | 95.21M | 92.43M | 95.07M |
| Net interest income | - | 170.59M | 92.47M | 91.80M | 93.81M |
| Income tax expense | 310.62M | 305.67M | 270.74M | 194.25M | 163.43M |
| Total revenue | 3049.99M | 3778.04M | 4516.54M | 3950.64M | 3223.55M |
| Total operating expenses | 1540.98M | 1989.15M | 2418.58M | 3228.23M | 2682.16M |
| Cost of revenue | 845.53M | 946.29M | 1122.42M | 1012.32M | 813.21M |
| Total other income expense net | 571.20M | 303.12M | 264.72M | - | - |
| Net income from continuing ops | - | 840.05M | 969.51M | 722.77M | 556.67M |
| Net income applicable to common shares | - | - | - | 722.77M | 556.67M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 10783.99M | 10041.53M | 9573.99M | 8231.86M | 7203.96M |
| Intangible assets | 15.73M | 23.32M | 32.79M | 47.35M | 66.43M |
| Other current assets | 47.19M | 93.28M | 87.88M | 32.01M | 35.06M |
| Total liab | 2717.05M | 2574.63M | 2539.22M | 1849.34M | 1302.48M |
| Total stockholder equity | 8066.94M | 7466.90M | 7034.77M | 6382.53M | 5901.48M |
| Other current liab | 1615.29M | 1624.49M | 1505.79M | 493.55M | 378.95M |
| Common stock | 87.72M | 87.66M | 87.66M | 87.66M | 87.66M |
| Capital stock | - | 87.66M | 87.66M | 87.66M | 87.66M |
| Retained earnings | - | 6726.44M | 6326.28M | 6367.61M | 5879.00M |
| Other liab | - | - | - | 182.83M | 196.78M |
| Good will | 166.06M | 165.96M | 165.96M | 165.96M | 165.96M |
| Other assets | 0.00M | - | -7004.91M | 19.22M | 20.46M |
| Cash | 7193.62M | 6140.15M | 5888.78M | 5026.27M | 4205.72M |
| Total current liabilities | 2511.87M | 2450.00M | 2433.72M | 1665.59M | 1098.37M |
| Current deferred revenue | 222.00M | - | 17.96M | - | - |
| Net debt | -6858.50M | -5793.63M | -5587.45M | - | - |
| Short term debt | 334.33M | 338.27M | 300.97M | - | - |
| Short long term debt | - | 330.00M | 300.00M | - | 0.00M |
| Short long term debt total | 335.11M | 346.53M | 301.33M | - | - |
| Other stockholder equity | 7979.22M | 652.81M | 620.82M | -494.89M | -487.32M |
| Property plant equipment | - | - | - | 1216.94M | 1252.00M |
| Total current assets | 9310.15M | 8598.52M | 8154.73M | 6782.40M | 5699.11M |
| Net tangible assets | - | - | - | 6169.22M | 5669.10M |
| Short term investments | 376.88M | 350.02M | 20.00M | 20.23M | - |
| Net receivables | 1000.72M | 1201.88M | 1260.37M | 1042.54M | 866.05M |
| Inventory | 691.74M | 813.19M | 897.71M | 657.66M | 587.96M |
| Accounts payable | 340.24M | 402.96M | 484.79M | 308.75M | 228.62M |
| Accumulated other comprehensive income | - | - | 97.79M | - | - |
| Non currrent assets other | - | - | 4.62M | - | - |
| Non current assets total | 1473.84M | 1443.01M | 1419.26M | 1449.46M | 1504.85M |
| Capital lease obligations | - | 16.53M | 1.33M | 7.44M | 14.91M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 150.33M | -272.11M | -49.54M | 6.67M | 8.74M |
| Change to liabilities | - | - | - | 147.36M | 73.60M |
| Total cashflows from investing activities | 222.03M | -272.11M | -49.54M | -45.42M | 395.01M |
| Net borrowings | -4.95M | 30.00M | 300.00M | -7.68M | -378.03M |
| Total cash from financing activities | -375.01M | -392.48M | -26.74M | -250.04M | -828.93M |
| Change to operating activities | - | - | - | 370.99M | 176.71M |
| Net income | 1269.27M | 1145.72M | 1240.25M | 722.77M | 556.67M |
| Change in cash | 1048.89M | 251.38M | 862.51M | 820.54M | 262.71M |
| Begin period cash flow | 6140.15M | 5888.78M | 5026.27M | 4205.72M | 3943.01M |
| End period cash flow | 7189.05M | 6140.15M | 5888.78M | 5026.27M | 4205.72M |
| Total cash from operating activities | 1172.03M | 963.13M | 932.63M | 1109.68M | 703.15M |
| Issuance of capital stock | - | - | - | 0.00M | 3.66M |
| Depreciation | 70.88M | 68.73M | 177.10M | 185.86M | 182.39M |
| Other cashflows from investing activities | 269.60M | 183.05M | 84.25M | 73.88M | 388.92M |
| Dividends paid | 355.04M | 407.92M | 317.27M | 241.73M | 453.07M |
| Change to inventory | 182.06M | 169.97M | -240.05M | -69.70M | -140.13M |
| Change to account receivables | 166.06M | 51.76M | -290.75M | -158.71M | -66.97M |
| Other cashflows from financing activities | -15.03M | -14.56M | -9.47M | -0.63M | -1.49M |
| Change to netincome | - | - | - | -88.90M | -79.12M |
| Capital expenditures | 197.91M | 140.11M | 144.32M | 129.46M | 93.63M |
| Change in working capital | 502.52M | 221.96M | -93.62M | 289.94M | 43.21M |
| Stock based compensation | - | - | - | 0.00M | 0.03M |
| Other non cash items | -670.64M | -473.28M | -391.10M | -122.21M | -118.94M |
| Free cash flow | 974.13M | 823.02M | 788.31M | 980.21M | 609.52M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSWYY China Shineway Pharmaceutical Group Ltd ADR |
3.39 19.24% |
21.01 | 6.23 | 163.93 | 1.18 | 0.68 | 0.03 | 0.09 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.
Luan Cheng District, Shijiazhuang, China, 051430
86 31 1880 30066
2822
| Name | Title | Year Born |
|---|---|---|
| Mr. Zhenjiang Li | Co-Founder & Exec. Chairman | 1955 |
| Ms. Yunxia Xin | Co-Founder & Exec. Director | 1963 |
| Mr. Huimin Li | Exec. Director | 1968 |
| Mr. Bun Ching Lee | Financial Controller & Company Sec. | 1973 |
| Mr. King Kuen Hung | Director of Investor Relation | 1966 |
| Mr. Yudong Zhang | Gen. Mang. of Sales & Marketing | 1974 |
| Mr. Tiejun Liu | Exec. Director | 1974 |
| Mr. Zhenjiang Li | Co-Founder & Executive Chairman | 1955 |
| Ms. Yunxia Xin | Co-Founder & Executive Director | 1963 |
| Mr. Huimin Li | Executive Director | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.